Argus Upgrades Teladoc (TDOC) to Buy

Argus analyst John Eade upgraded Teladoc (NYSE: TDOC) from Hold to Buy with a price target of $95.00.

The analyst comments "We are raising our rating on Teladoc Health Inc. (NYSE: TDOC) to BUY from HOLD and setting a price target of $95. After years of operating losses despite robust revenue growth, Teladoc is now on a clear path to profitability. The company's 4Q21 results showed growth in membership, utilization, and per member revenue. In 2021, cash flow from operations also swung to positive $194.0 million from negative $53.5 million in 2020. In addition, management has projected higher adjusted EBITDA margins in the second half of 2022. Given current trends in revenue and operating expenses, we see the potential for positive EPS by 4Q22."

For an analyst ratings summary and ratings history on Teladoc click here. For more ratings news on Teladoc click here.

Shares of Teladoc closed at $72.49 yesterday.

You May Also Be Interested In